Introduction
Anaemia is a common complication of chronic kidney disease (CKD). It is associated with morbidity and mortality as well as reduced exercise tolerance and quality of life. Iron therapies and erythropoiesis stimulating agents (ESAs) remain the mainstay of the management of patients with renal anaemia, minimising the need for blood transfusions. This chapter describes analyses of the management of anaemia in dialysis patients in the UK in 2016. The attainment of parameters is compared at a renal centre and national level as well as against national performance measures as set out in the Renal Association (RA) practice guidelines which are published online.
The audit measures applied to the care of dialysis patients in 2016 and recommended in this chapter are taken from the Renal Association Clinical Practice Guideline for Anaemia of CKD (5th edition) published online in 2010 [1] . Table 7 .1 lists the audit measures recommended in these guidelines alongside those parameters measured in this chapter and where applicable reasons for exclusion.
In mid-2017, an updated 6th edition of the Renal Association guideline was published [2] which endorses the National Institute for Health and Care Excellence (NICE) guideline for anaemia management in chronic kidney disease 2015 [3] . The recommended haemoglobin targets remain the same although the indices for assessing patient iron status have changed. Specifically, percentage hypochromic red blood cells (HRC) or reticulocyte haemoglobin content (CHr) are recommended as preferable markers of iron deficiency to serum ferritin or transferrin saturation. The impact this will have on both clinical practice and centre reporting through the UKRR remains to be seen. The guidelines acknowledge the practical challenges of measuring HRC due to the need for timely testing on specialist analysers. CHr does not currently form part of the UKRR renal dataset and further work will be undertaken by the UKRR in collaboration with renal centres to explore the ability to report this variable. Internationally, The Kidney Disease Improving Global Outcomes (KDIGO) Clinical Practice Guideline for Anemia in Chronic Kidney Disease was published in August 2012 [4] and is yet to be updated.
Methods
Most of the analyses in this chapter use the incident or prevalent renal replacement therapy (RRT) cohorts for 2016. Some analyses use data from earlier years. Haemoglobin levels are given in g/L as the majority of UK laboratories have now switched to reporting using these units rather than g/dl.
The UKRR extracted quarterly data electronically from renal centres in England, Wales and Northern Ireland (E,W & NI) taking the latest available result from each quarter. Data from Scotland were provided by the Scottish Renal Registry (SRR).
For the analyses of Hb for incident patients, those patients commencing RRT on PD or HD were included whilst those receiving a pre-emptive transplant were excluded. Hb measurements from after starting dialysis but still within the same quarter of the year were used. Therefore, depending on when in the quarter a patient started RRT the Hb data could be from zero to 90 days later. Due to possible deficiencies with extract routines it is possible that a small number of the values extracted electronically may actually be from before the person started dialysis. This problem will not occur for Scottish data. Patients who died within the first 90 days on treatment were excluded. Results are also shown with the cohort subdivided into early and late presenters (date first seen by a nephrologist, 90 or more days and less than 90 days before starting dialysis respectively). For these analyses only centres with at least 75% completeness of presentation time data were included.
For the analyses of prevalent dialysis patients those patients receiving dialysis on 31 December 2016 were included if they had been on the same modality of dialysis in the same centre for at least three months. In order to improve completeness, the last available measurement for each patient from the last two quarters was used for Hb and from the last three quarters for ferritin.
The completeness of data items were analysed at both centre and country level. All patients were included in analyses but centres with less than 50% completeness were excluded from the caterpillar and funnel plots showing centre level results. Centres providing relevant data from less than ten patients were also excluded from the plots. The number preceding the centre name in the caterpillar plots is the percentage of patients who have data missing.
Summary statistics including minimum, maximum, interquartile ranges (IQR), averages (mean and median) and standard deviations were calculated. The median values and the IQRs are shown using caterpillar plots. The percentages achieving standards were also calculated and these are displayed using caterpillar plots with the percentages meeting the targets and 95% confidence intervals (CIs) shown. Funnel plots show the distribution of the percentages meeting the targets and also whether any of the centres were significantly different from the average. Longitudinal analyses were performed to show overall changes in achievement of standards over time.
Erythropoietin data from the last quarter of 2016 were used to define which patients were receiving erythropoietin stimulating agents (ESAs). Scotland was excluded from this analysis due to incomplete data. Each individual was defined as being on ESA if a drug type and/or a dose was present in the data. Centres reporting fewer than 60% of HD patients or fewer than 40% of PD patients being treated with ESAs were considered to have incomplete data and were excluded from further analysis. It is recognised that these exclusion criteria are relatively arbitrary but they are in part based upon the frequency distribution graph of centres' ESA use as it appears in the data. The percentage of patients on ESAs was calculated from these data and incomplete data returns risk seriously impacting on any conclusions drawn.
For analyses of ESA dose, values are presented as weekly erythropoietin dose. Doses of less than 150 IU/week (assumed to be darbepoietin or methoxy polyethylene glycol-epoetin beta) were harmonised with erythropoietin data by calculating a weekly dose and multiplying by 200. No adjustments were made with respect to route of administration. Patients who were not receiving ESAs were not included in analyses of dose (rather than being included with dose = 0). Many centres provided data on ESA dose but not on ESA frequency. The ESA dose field is defined as the weekly dose and the dose is presumed to have been converted accordingly on submission to the UKRR. This may be an incorrect assumption for a number of patients and this needs to be considered when interpreting the ESA information.
Starting with the cohort of patients receiving ESAs in the final quarter of the year and having a dose value present for that quarter, any further dose values available from the earlier three quarters of the year were used (provided the patient was on the same treatment and receiving the same drug in those quarters). The average (mean) of the available values was then used in analyses rather than the dose in the final quarter.
The ESA data were collected electronically from renal IT systems but in contrast to laboratory linked variables the ESA data required manual data entry. The reliability depended upon the data source, whether the entry was linked to the prescription or whether the prescriptions were provided by the primary care physician. In the latter case, doses may not be as reliably updated as the link between data entry and prescription was indirect. The three centres in North Wales, namely Wrexham, Bangor and Clwyd used several databases including their renal IT system for ESA data in HD patients and were therefore excluded from the HD ESA analysis.
Cambridge renal centre (Addenbrooke's) was unable to submit their 2016 (and 2015) data at patient level prior to the UKRR closing the database and only provided summary numbers of patients starting RRT by treatment modality. This centre is therefore excluded from most analyses in this chapter.
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The median Hb of patients on HD in the UK in 2016 was 111 g/L (IQR 102-119) and is shown in table 7.4. For HD patients, 80% had a Hb 5100 g/L. Figure 7 .7 shows the median Hb in HD patients by renal centre. Figure 7 .8 shows the proportion of patients by centre with Hb within the Renal Association guideline range (100-120 g/L) and figure 7.9 shows the distribution of Hb within, above and below this range.
Funnel plots for the percentage of patients with Hb 5100 g/L (figure 7.10) and between 100-120 (figure 7.11) are shown with 95% and 99.9% confidence limits. Table 7 .4 can be used to identify centres in these funnel plots.
Haemoglobin in prevalent peritoneal dialysis patients
The median Hb of patients on PD in the UK in 2016 was 111 g/L (IQR 102-120, table 7.5). For PD patients, 79% had a Hb 5100 g/L. Figure 7 .12 shows the median Hb in PD patients by centre. Figure 7 .13 shows the proportion of patients by centre with Hb within the Renal Association guideline range (100-120 g/L) and figure 7.14 shows the distribution of Hb within, above and below this range. 
Relationship between Hb in incident and prevalent dialysis patients
The relationship between the percentage of incident and prevalent patients with Hb 5100 g/L is shown in figure 7 .17. As expected, all centres had a higher percentage of prevalent patients achieving a Hb 5100 g/L than of incident patients.
Changes in achievement of Hb 5100 g/L by year of start in both incident and prevalent patients is shown in figure 7. 18. This shows a falling trend in the proportion of patients achieving a Hb 5100 g/L over the last decade.
Ferritin in prevalent haemodialysis patients
The median and IQR for serum ferritin for patients treated with HD are shown in figure 7 .19. The percentages with serum ferritin 5100 mg/L, .200 mg/L to 4500 mg/L, and 5800 mg/L are shown in figures 7.20, 7.21 and 7.22 respectively. The median serum ferritin in HD patients was 410 mg/L with 94% of HD patients achieving a serum ferritin 5100 mg/L.
Ferritin in prevalent peritoneal dialysis patients
The median and IQR for serum ferritin for patients treated with PD are shown in figure 7 .23. The percentages with serum ferritin 5100 mg/L, .100 mg/L to 4500 mg/L, and 5800 mg/L are shown in figures 7.24, 7.25 and 7.26 respectively. The median serum ferritin in PD patients was 306 mg/L with 88% of PD patients achieving a serum ferritin 5100 mg/L. ESA prescription and association with achieved haemoglobin Figures 7.9 and 7.14 show the distribution of Hb concordance with the Renal Association guideline (100-120 g/L). Not all patients with Hb .120 g/L were receiving ESA. The consensus was that these patients should not be included in the group of patients not meeting this target. There are two reasons: first, the high Hb remains largely outside the control of the clinician; secondly, the trials suggesting it may be detrimental to achieve a high Hb in renal patients were based upon patients treated with ESAs [5] [6] [7] ESA prescription: age and modality associations The proportion of patients on ESA was higher for HD (90%) than for PD (70%). This difference was maintained across all age groups (figure 7.31). The proportion of patients with Hb 5100 g/L without requiring an ESA is shown (by age group and modality) in figure 7.32.
Erythropoiesis stimulating agents in prevalent haemodialysis patients
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ESAs and time on renal replacement therapy
The percentage of patients on ESA by time on RRT and dialysis modality is shown in figure 7 .33. This is a cross-sectional analysis of patients at the end of 2016.
Patients who had previously changed RRT modality were included in the analysis. The proportion of PD patients receiving ESA rises with duration of RRT from 70% after 3-12 months to 78% after ten or more years.
Resistance to ESA therapy The Renal Association guidelines define resistance to ESA therapy as 'failure to reach the target Hb level despite sc epoetin dose 300 IU/kg/week (450 IU/kg/ week iv epoetin) or darbepoetin dose >1.5 mcg/kg/ week' [1] . Figure 7 .34 shows the frequency distribution of weekly ESA dose adjusted for weight by treatment modality. Centres included in this analysis were restricted to those with good completeness for weight (.75%) and ESA data. Thirty two centres were included for HD data and 16 centres for PD. The prevalence of PD patients receiving over 300 IU/kg/week was 3.0% with 5.7% of HD patients receiving more than 300 IU/kg/week and 1.2% more than 450 IU/kg/week.
Success with guideline compliance
The percentage of prevalent dialysis patients achieving a Hb 5100 g/L by year (1998-2016) is shown in figure 7 .35. This has shown a gradual fall in achievement of this guideline over the last decade. Table 7 .6 shows that the percentage of all patients treated with an ESA and having Hb .120 g/L ranged between 8-32% for HD and between 0-32% for PD. Table 7 .7 shows the percentage completeness for ESA type, dose, route and frequency for centres reporting ESA data. Even for this group of centres which is already restricted to those with useable ESA data, completeness of frequency and administration route averaged below 50%. Roughly half of the centres had very good completeness for these items and the other half did not submit at all. Pyart/Gilg/Williams
Discussion
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The goal of anaemia management in CKD is the maintenance of acceptable Hb concentrations. Prior to the development of ESAs, severe anaemia with intermittent blood transfusions were the norm. Unexpectedly, several studies subsequently showed adverse outcomes with physiological correction of Hb with ESAs [5] [6] [7] , resulting in clinical guidelines advocating a target Hb of 100-120 g/L for patients receiving ESA therapy. This evolution in understanding of optimal Hb targets is reflected in historic analyses in figures 7.18 and 7.35. Guidelines continue to underline the importance of individualising therapy taking into account the time it takes for ESA therapy to work and the small but significant risk associated with ESA therapy.
Haemoglobin outcomes were similar for both HD and PD patients with proportions of prevalent patients compliant with Hb 100-120 g/L of 59% and 55% respectively. Prevalent HD patients had a higher median serum ferritin (410 mg/L vs 306 mg/L), a higher proportion of patients requiring ESAs (90% vs 70%) and a higher median ESA dose in those receiving ESAs (7,750 IU/ week vs 4,500 IU/week) compared with prevalent PD patients.
As expected, a greater proportion of prevalent dialysis patients than incident patients attained a Hb 5100 g/L (80% vs 47%). Only 34% of late presenters achieved a Hb 5100 g/L suggesting that part of this difference was because there was less opportunity for anaemia to be treated with iron or ESAs. The fact that even in the early presenting incident group of patients only 50% achieved Hb 5100 g/L suggests that opportunity is only part of the explanation for incident patients. Alternative explanations include the fact that a number of patients commenced dialysis at the time of an acute illness when acute anaemia is common.
The proportion of patients achieving a serum ferritin of 5100 mg/L was 94% of HD patients and 88% of PD patients. It is recommended that patients be iron replete to achieve and maintain optimal target Hb, while avoiding iron overload and potential toxicity as reflected in the guideline audit measures. Iron repletion helps to minimise both the need to initiate ESA therapy and the dose of ESA subsequently required. The revised Renal Association anaemia guideline published midway through the 2017 data collection period [2] recommends that percentage hypochromic red blood cells or reticulocyte haemoglobin are preferable markers of iron deficiency than serum ferritin or transferrin saturation. Renal centres will need to consider the incorporation of these changes into local guidelines. The UKRR will continue to work in collaboration with renal centres to report these new data items as well as improve data completeness for ESA and iron therapy. As of 2016, the analysis of ESA usage continued to be limited by incomplete data returns. From the available data, 90% of HD patients and 70% of PD patients were receiving ESAs. The attainment of Hb targets correlated poorly with median ferritin and ESA usage.
There continued to be variation in concordance with anaemia guidelines between UK renal centres.
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